|
This is a promotional email for UK Healthcare Professionals, sent on behalf of Takeda UK Ltd. A link to Prescribing Information and Adverse Event reporting can be found at the end of this email.
Problems viewing this email? View it in your browser. |
|
|
|
|
| A Day in an ADHD Clinic: diagnosis and management of ADHD in adult patients, a discussion of appropriate treatments based on comorbid physical health conditions |
|
|
|
|
|
| Dr Joe Johnson, Consultant Psychiatrist, and Sarah Morris, Pharmacist Prescriber provide expert insight into how General Psychiatrists and other healthcare providers can recognise and manage ADHD in adult patients and discuss the management of comorbid physical health conditions alongside ADHD, using real life patient case study examples. |
|
|
|
|
|
|
| This podcast covers: |
 |
What is ADHD, and how it presents in adult patients. |
 |
The impact of comorbid physical health conditions that can present alongside ADHD, including epilepsy, thyroid problems, high blood pressure and cardiovascular risk. |
 |
Best practices in managing both ADHD and these comorbid physical health conditions. |
 |
How to manage ADHD in older patients. |
|
|
 |
|
| Clicking on this button will take you through to the podcast which is initiated and developed by Takeda |
|
|
|
|
| For more ADHD podcasts and resources, please visit the ADHD eForum at www.ADHDeForum.co.uk |
| Clicking this link will take you to the ADHD eForum website, initiated, organised and funded by Takeda (registration required) |
|
|
|
| |
| Help your patients manage their ADHD symptoms with Elvanse Adult (lisdexamfetamine dimesylate) |
|
 |
Recommended by NICE as a first line medication choice for adults with ADHD1 |
|
Prodrug technology for consistent symptom control2-4 |
|
Taken once-daily for 14-hour core symptom control2,5 |
|
Significantly improved symptoms as rapidly as week 1, sustained long-term6,7 |
|
Significantly improved executive function and quality of life vs. placebo at 10 weeks8,9 |
|
The most frequently reported adverse reactions (≥1/10) with Elvanse Adult are decreased appetite, dry mouth, headache and insomnia5 |
|
|
|
 |
|
|
| Clicking this button will take you to a Takeda resource on BMJ.com for ADHD/Elvanse Adult. |
|
|
|
|
|
Elvanse Adult is indicated as part of a comprehensive programme for attention deficit/hyperactivity disorder in adults.5
Elvanse Adult is not indicated in all adult patients and the decision to use the medicinal product must take into consideration the profile of the patient, including a thorough assessment of the severity and chronicity of the patient’s symptoms, the potential for abuse, misuse or diversion, and clinical response to any previous pharmacotherapies for the treatment of ADHD.5
Elvanse Adult treatment must be under the supervision of a specialist in behavioural disorders.5 |
| References |
| 1. |
NICE guidelines NG87 (2018). Attention deficit hyperactivity disorder: diagnosis and management. Available at www.nice.org.uk/guidance/ng87 (accessed June 2023). |
| 2. |
Wigal T et al. Behav Brain Funct 2010;6:34. |
| 3. |
Ermer JC et al. Clin Drug Investig 2016;36:341–56. |
| 4. |
Ermer J et al. J Clin Pharmacol 2010;50:1001–10. |
| 5. |
Elvanse Adult Summary of Product Characteristics. Available at: www.medicines.org.uk (accessed June 2023). |
| 6. |
Adler LA et al. J Clin Psychiatry 2008;69:1364−73. |
| 7. |
Weisler R et al. CNS Spectr 2009;14:573−85. |
| 8. |
Adler LA, et al. J Clin Psychiatry 2013;74(7):694–702. |
| 9. |
Adler LA et al. BMC Psychiatry 2013;13:253. |
|
|
| Click here for Prescribing Information |
|
Job Code: C-APROM/GB/NS/0535
Date of Preparation: June 2023 |
|
|
|
This email has been forwarded to you by Data4NHS, on behalf of Takeda UK Ltd.
Manage your Data4NHS profile by submitting your changes HERE.
View our privacy policy HERE.
UNSUBSCRIBE. |
|
